PROBLEMATIC POLYPHARMACY IN OUTPATIENT THERAPY OF CHILDREN: POTENTIAL RISKS OF DRUG INTERACTIONS
Article PDF (Українська)

How to Cite

Khaitovych , M., Sova, V. A., Kyrylchuk , K. Y., Sytnyk І., Polovynka , V., Теmіrоvа О., & Turchak , D. (2022). PROBLEMATIC POLYPHARMACY IN OUTPATIENT THERAPY OF CHILDREN: POTENTIAL RISKS OF DRUG INTERACTIONS. Medical Science of Ukraine (MSU), 18(1), 35-39. https://doi.org/10.32345/2664-4738.1.2022.06

Abstract

Relevance. The development of medical and pharmaceutical technologies has allowed ensuring the quality of life of children even with severe chronic diseases, but often the treatment of such children is associated with polypharmacy. Objective is to assess the risks of drug interactions in children with polypharmacy. Materials and methods. The course of pharmacotherapy of 54 children with atopic diseases, diseases of the gastrointestinal tract, parasitic infestation, inflammatory diseases of the genital organs, etc. aged from birth to 17 years, who received simultaneously from 5 to 11 drugs (average 6.4 ± 1.5 drugs)

Results. Problematic polypharmacy was founded in 31 children (75.0% of schoolchildren and 38.5% of preschool children) with polypharmacy. Among them, 22 patients (71.0%) had pharmacokinetic risks, and 17 children (54.8%) had pharmacodynamic interactions. Among the causes of pharmacokinetic interaction – the use of inhibitors (omeprazole, etc.) and inducers (phenobarbital, St. John's wort, etc.) metabolism, pharmacodynamic interaction – the simultaneous use of several glucocorticoids, drugs with similar organ toxicity, and more.

Conclusions. Outpatient use of 5 or more drugs is combined in more than half of children at risk of their interaction, development of side effects or reduced effectiveness of treatment.

https://doi.org/10.32345/2664-4738.1.2022.06
Article PDF (Українська)

References

National Survey of Children’s Health. NSCH 2018 19: Number of Current or Lifelong Health Conditions, Nationwide, Age in 3 Groups. Accessed February 24, 2021.

View at:

Publisher Site: https://www.childhealthdata.org/

Huth K, Vandecruys P, Orkin J, Patel H. Medication safety for children with medical complexity. Paediatrics & Child Health. 2020; 25(7):473-474. DOI: 10.1093/pch/pxaa105.

View at:

Publisher Site: https://academic.oup.com/pch/article/25/7/473/5952405?login=false

PubMed: https://pubmed.ncbi.nlm.nih.gov/33178368/

PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606167/

Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatrics. 2017;17(1):230. DOI: 10.1186/s12877-017-0621-2.

View at:

Publisher Site: https://bmcgeriatr.biomedcentral.com/articles/10.1186/s12877-017-0621-2

PubMed: https://pubmed.ncbi.nlm.nih.gov/29017448/

PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635569/

Taghy N, Cambon L, Cohen J-M, Dussart C. Failure to Reach a Consensus in Polypharmacy Definition: An Obstacle to Measuring Risks and Impacts – Results of a Literature Review. Therapeutics and Clinical Risk Management. 2020;16:57-73. DOI: 10.2147/TCRM.S214187.

View at:

Publisher Site: https://www.dovepress.com/failure-to-reach-a-consensus-in-polypharmacy-definition-an-obstacle-to-peer-reviewed-fulltext-article-TCRM

PubMed: https://pubmed.ncbi.nlm.nih.gov/32103967/

PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023902/

Baker C, Feinstein JA, Ma X, Bolen S, Dawson NV, Golchin N, Horace A, Kleinman LC, Meropol SB, Knight EMP, Winterstein AG, Bakaki PM. Variation of the Prevalence of Pediatric Polypharmacy: A Scoping Review. Pharmacoepidemiol Drug Saf. 2019 March; 28(3): 275-287. DOI:10.1002/pds.4719.

View at:

Publisher Site: https://onlinelibrary.wiley.com/doi/10.1002/pds.4719

PubMed: https://pubmed.ncbi.nlm.nih.gov/30724414/

PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461742/

Feinstein JA, Feudtner C, Valuck RJ, Kempe A. The depth, duration, and degree of outpatient pediatric polypharmacy in Colorado fee-for-service Medicaid patients. Pharmacoepidemiol Drug Saf. 2015;24(10):1049-57. DOI: 10.1002/pds.3843.

View at:

Publisher Site: https://onlinelibrary.wiley.com/doi/10.1002/pds.3843

PubMed: https://pubmed.ncbi.nlm.nih.gov/26248529/

Khezrian M, McNeil CJ, Murray AD, Myint PK. An overview of prevalence, determinants and health outcomes of polypharmacy. Ther Adv Drug Saf. 2020; 11: 2042098620933741. DOI: 10.1177/2042098620933741.

View at:

Publisher Site: https://journals.sagepub.com/doi/10.1177/2042098620933741

PubMed: https://pubmed.ncbi.nlm.nih.gov/32587680/

PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294476/

Duerden M, Avery T, Payne R. Polypharmacy and medicines optimisation. Making it safe and sound. The King’s Fund. 2013. – 56 p.

View at:

Publisher Site: https://www.kingsfund.org.uk/publications/polypharmacy-and-medicines-optimisation

URL: https://www.kingsfund.org.uk/sites/default/files/field/field_publication_file/polypharmacy-and-medicines-optimisation-kingsfund-nov13.pdf

[Rektodelt 100]. Regulatory and directive documents of the Ministry of Health of Ukraine [in Ukrainian].

View at:

Publisher Site: https://mozdocs.kiev.ua/likiview.php?id=813

National transfer of medicinal products «liki control» [19747]. [in Ukrainian].

View at:

Publisher Site: https://likicontrol.com.ua/

Asher GN, Corbett AH, Hawke RL. Common Herbal Dietary Supplement – Drug Interactions. Am Fam Physician. 2017;96(2):101-107.

View at:

PubMed: https://pubmed.ncbi.nlm.nih.gov/28762712/

Curcumin. DrugBank Accession Number DB11672.

View at:

Publisher Site: https://go.drugbank.com/drugs/DB11672

St. John's Wort. DrugBank Accession Number DB01323.

View at:

Publisher Site: https://go.drugbank.com/drugs/DB01323

Jeon S-M, Park S, Rhie SJ, Kwon J-W. Prescribing patterns of polypharmacy in Korean pediatric patients. PLoS One. 2019; 14(10): e0222781. DOI: 10.1371/journal.pone.0222781.

View at:

Publisher Site: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0222781

PubMed: https://pubmed.ncbi.nlm.nih.gov/31574095/

PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6773215/

Drake RE. Overmedicating vulnerable children in the U.S. Epidemiology and Psychiatric Sciences. 2019; 28(4): 358-359. DOI: 10.1017/S2045796018000689

View at:

Publisher Site: https://www.cambridge.org/core/journals/epidemiology-and-psychiatric-sciences/article/overmedicating-vulnerable-children-in-the-us/427175066064714EDDD9F37D44DA0F45

PubMed: https://pubmed.ncbi.nlm.nih.gov/30474575/

PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6999034/

Golchin N, Johnson H, Bakaki PM, Dawson N, Knight EMP, Meropol SB, Liu R, Feinstein JA, Bolen SD, Kleinman LC, Horace A. Outcome measures in pediatric polypharmacy research: a scoping review. Drugs Ther Perspect. 2019; 35(9): 447-458. DOI:10.1007/s40267-019-00650-8.

View at:

Publisher Site: https://link.springer.com/article/10.1007/s40267-019-00650-8

PubMed: https://pubmed.ncbi.nlm.nih.gov/32256042/

PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123381/

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.